---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-26-000062"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2026-08-06T11:11:10+00:00"
generated_at: "2026-08-06T11:15:32.902455+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tarsus Pharmaceuticals raises $125M in oversubscribed PIPE financing at $56/share

## Summary
- Gross proceeds of ~$125M from sale of 2,098,519 shares at $56.00 and pre-funded warrants for 133,625 shares at $55.9999.
- PIPE includes participation from Alkeus investors (TCGX, Bain Capital, Wellington) and new investors (ADAR1, Sirenia, RTW, Vestal Point).
- Proceeds to fund clinical development, commercial activities, and general corporate purposes; closing expected Aug 7, 2026.
- PIPE is in connection with pending acquisition of Alkeus Pharmaceuticals (announced separately).
- Barclays lead placement agent; BofA Securities and William Blair co-placement agents.

## SEC filing metadata
- accession: 0001819790-26-000062
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2026-08-06T11:11:10+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979026000062/0001819790-26-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979026000062/tars-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-26-000062
- JSON: https://secwatch.observer/filing/0001819790-26-000062.json
- Plain text: https://secwatch.observer/filing/0001819790-26-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.